rood blauwe elepsis logo Belegger.nl

Sopheon Terug naar discussie overzicht

Sopheon maart 2020

16 Posts
| Omlaag ↓
  1. Bertus S 19 maart 2020 08:02
    Audited Results Statement for the Year to 31 December 2019
    Sopheon plc, the international provider of software, expertise, and best practices for Enterprise Innovation Performance, is pleased to announce its results for the year ended 31 December 2019, in line with market expectations, together with an outlook for the current year.

    Highlights:
    Revenue: $30.3m (2018: $33.9m)
    Adjusted EBITDA1: $6.4m (2018: $9.4m)
    PBT: $2.5m (2018: $6.4m)
    Net cash: $19.4m (2018: $16.7m)
    Fourth quarter delivered 23 license transactions from annual total of 47 (2018:57) and 18 new customer wins (2018: 18).
    ARR rose from $14.8m at the start of 2019 to $15.9m at the end of the year. Full year 2020 revenue visibility2 is now $21.2m (Last year at this time: $20.6m).
    Transition to a SaaS business has started and the proportion of such business in the pipeline is at
    45 percent of total software related opportunity.
    Robust balance sheet and cash position. Dividend maintained at 3.25p per share (2018: 3.25p).
    Barry Mence, Chairman, commented: “It was good to see the inherent discipline in our business delivering another profitable and cash generative year, and our closing net asset and cash positions at historic highs. Consistent with our expectation after a slow first half, momentum rebounded sharply in the final quarter, which was one of the strongest on record for deal flow. Sopheon has a strong track record in a market that we believe is set to expand rapidly. Overall, coronavirus unknowns aside, we remain confident of growing commercial traction in the coming year. To underline this confidence, I am pleased to announce that in spite of a challenging year we are maintaining our dividend at 3.25p per share.”

    For further information contact:

    Barry Mence (Chairman)
    Arif Karimjee (CFO) Sopheon plc + 44 (0) 1276 919 560
    Carl Holmes/Giles Rolls (Corporate Finance)
    Alice Lane/Sunila de Silva (ECM) finnCap Ltd + 44 (0) 20 7220 0500
    About Sopheon
    Sopheon (LSE: SPE) partners with customers to provide complete enterprise innovation management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon’s Accolade® solution provides unique, fully integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon’s solutions have been implemented by over 250 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange.

    www.sopheon.com/audited-results-state...

    Bertus S.
  2. [verwijderd] 19 maart 2020 08:44
    Allemaal min of meer als verwacht. Visibility licht hoger dan vorig jaar op dit tijdstip. Dividend blijft in stand (maar is nog geen vetpot natuurlijk).

    Onder kopje Outlook wordt maar zijdelings het coronavirus genoemd; hoop niet dat ze het onderschatten; en dat ze inderdaad maar weinig last gaan ondervinden. Ze hebben een hoop klanten in de levensmiddelen branche natuurlijk, die hier weinig van zullen merken.
  3. Gartje 1 april 2020 09:14
    Volgens mij heb je ze binnen nu! Vind het wel een probleem dat je zo moeilijk kan kopen en verkopen bij dit aandeel!
  4. Lord Enki 1 april 2020 10:44
    Klopt.
    Kunnen kopen via Binck.
    Werkt prima.
    Vanochtend geluk gehad.
    Zit er voor de langere termijn in, dus ik ben tevreden met deze prijs.

    Draadje verder in de post voor april..

  5. Gartje 7 april 2020 16:34
    Ik zat ook voor de langere termijn, maar na 15 jaar moet ik toch ook eerlijk zeggen! Je moet wel een verdomde lange adem hebben voor Sopheon, gaan we ooit die 15 pond nog zien pfff
  6. abc123xyz987 8 april 2020 22:57
    quote:

    marblesthegame schreef op 8 april 2020 20:04:

    Nieuwe klant ??

    Arcelik Global

    twitter.com/sopheon

    We’re excited to announce a new panelist!
    @ArcelikGlobal's Cemil Inan will now join
    Nee, is al een poosje klant (van oa Beko, Grundig).

    Groet ABC
16 Posts
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 6.997
AB InBev 2 5.479
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.123
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.450
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.623
Aedifica 3 900
Aegon 3.258 322.602
AFC Ajax 537 7.084
Affimed NV 2 6.287
ageas 5.844 109.883
Agfa-Gevaert 14 2.046
Ahold 3.538 74.287
Air France - KLM 1.025 34.973
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.020
Alfen 16 24.234
Allfunds Group 4 1.468
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 403
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.485 114.806
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.834 242.589
AMG 971 133.002
AMS 3 73
Amsterdam Commodities 305 6.685
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 481
Antonov 22.632 153.605
Aperam 92 14.886
Apollo Alternative Assets 1 17
Apple 5 375
Arcadis 252 8.731
Arcelor Mittal 2.033 320.447
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.282
Aroundtown SA 1 219
Arrowhead Research 5 9.715
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.061
ASML 1.766 105.375
ASR Nederland 21 4.450
ATAI Life Sciences 1 7
Atenor Group 1 466
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.581
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.383